Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host

Infection and Immunity

Volumn 78, Issue 7, 2010, Pages 3036-3046

  Gronbach, Kerstin ^a   Eberle, Ute ^a   Müller, Martina ^a   Ölschläger, Tobias A ^b   Dobrindt, Ulrich ^b   Leithäuser, Frank ^c   Niess, Jan Hendrik ^c   Döring, Gerd ^a   Reimann, Jörg ^c   Autenrieth, Ingo B ^a   Frick, Julia Stefanie ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BACTERIUM MUTANT; BACTEROIDES VULGATUS; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ESCHERICHIA COLI; ESCHERICHIA COLI STRAIN NISSLE 1917; FLAGELLUM; INTESTINE EPITHELIUM; INTESTINE FLORA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADAPTIVE IMMUNITY; ANIMALS; CYTOKINES; ESCHERICHIA COLI; GENES, BACTERIAL; GENES, RAG-1; INTESTINES; METAGENOME; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; POLYMERASE CHAIN REACTION; PROBIOTICS; T-LYMPHOCYTES; TRANSLOCATION, GENETIC;

EID: 77953957401     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00218-10     Document Type: Article

References (46)

1. Backhed, F., S. Normark, E. K. Schweda, S. Oscarson, and A. Richter-Dahlfors. 2003. Structural requirements for TLR4-mediated LPS signalling: a biological role for LPS modifications. Microbes Infect. 5:1057-1063. (Pubitemid 37211466)
2. Baumgart, D. C., and S. R. Carding. 2007. Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627-1640. (Pubitemid 46722636)
3. Besselink, M. G., H. C. van Santvoort, E. Buskens, M. A. Boermeester, H. van Goor, H. M. Timmerman, V. B. Nieuwenhuijs, T. L. Bollen, B. van Ramshorst, B. J. Witteman, C. Rosman, R. J. Ploeg, M. A. Brink, A. F. Schaapherder, C. H. Dejong, P. J. Wahab, C. J. van Laarhoven, E. van der Harst, C. H. van Eijck, M. A. Cuesta, L. M. Akkermans, and H. G. Gooszen. 2008. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371:651-659.
4. Billips, B. K., A. J. Schaeffer, and D. J. Klumpp. 2008. Molecular basis of uropathogenic Escherichia coli evasion of the innate immune response in the bladder. Infect. Immun. 76:3891-3900.
5. Bjarnason, A., S. N. Adler, and I. Bjarnason. 2008. Probiotic prophylaxis in predicted severe acute pancreatitis. Lancet 372:114-115. (Pubitemid 351952253)
6. Bleich, A., J. P. Sundberg, A. Smoczek, R. von Wasielewski, M. F. de Buhr, L. M. Janus, G. Julga, S. N. Ukena, H. J. Hedrich, and F. Gunzer. 2008. Sensitivity to Escherichia coli Nissle 1917 in mice is dependent on environment and genetic background. Int. J. Exp. Pathol. 89:45-54.
7. Blum, G., R. Marre, and J. Hacker. 1995. Properties of Escherichia coli strains of serotype O6. Infection 23:234-236.
8. Blum-Oehler, G., S. Oswald, K. Eiteljorge, U. Sonnenborn, J. Schulze, W. Kruis, and J. Hacker. 2003. Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res. Microbiol. 154:59-66.
9. Boudeau, J., A. L. Glasser, S. Julien, J. F. Colombel, and A. Darfeuille-Michaud. 2003. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherentinvasive E. coli strains isolated from patients with Crohn's disease. Aliment. Pharmacol. Ther. 18:45-56.
10. Cannon, J. P., T. A. Lee, J. T. Bolanos, and L. H. Danziger. 2005. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur. J. Clin. Microbiol. Infect. Dis. 24:31-40.
11. Caviglia, R., I. Boskoski, and M. Cicala. 2008. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin. Drug Saf. 7:617-632.
12. Chen, Y., K. Chou, E. Fuchs, W. L. Havran, and R. Boismenu. 2002. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc. Natl. Acad. Sci. U. S. A. 99:14338-14343.
13. Flint, H. J., E. A. Bayer, M. T. Rincon, R. Lamed, and B. A. White. 2008. Polysaccharide utilization by gut bacteria: potential for new insights from genomic analysis. Nat. Rev. Microbiol. 6:121-131.
14. Frank, D. N., and N. R. Pace. 2008. Gastrointestinal microbiology enters the metagenomics era. Curr. Opin. Gastroenterol. 24:4-10.
15. Frick, J. S., K. Fink, F. Kahl, M. J. Niemiec, M. Quitadamo, K. Schenk, and I. B. Autenrieth. 2007. Identification of commensal bacterial strains that modulate Yersinia enterocolitica and dextran sodium sulfate-induced inflammatory responses: implications for the development of probiotics. Infect. Immun 75:3490-3497.
16. Grozdanov, L., C. Raasch, J. Schulze, U. Sonnenborn, G. Gottschalk, J. Hacker, and U. Dobrindt. 2004. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J. Bacteriol. 186:5432-5441. (Pubitemid 39038145)
17. Grozdanov, L., U. Zahringer, G. Blum-Oehler, L. Brade, A. Henne, Y. A. Knirel, U. Schombel, J. Schulze, U. Sonnenborn, G. Gottschalk, J. Hacker, E. T. Rietschel, and U. Dobrindt. 2002. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J. Bacteriol. 184:5912-5925.
18. Guenther, K., E. Straube, W. Pfister, A. Guenther, and A. Huebler. 2010. Severe sepsis after probiotic treatment with Escherichia coli Nissle 1917. Pediatr. Infect. Dis. J. 29:188-189.
19. Hilbert, D. W., K. E. Pascal, E. K. Libby, E. Mordechai, M. E. Adelson, and J. P. Trama. 2008. Uropathogenic Escherichia coli dominantly suppress the innate immune response of bladder epithelial cells by a lipopolysaccharideand Toll-like receptor 4-independent pathway. Microbes Infect. 10:114-121.
20. Hooper, L. V. 2009. Do symbiotic bacteria subvert host immunity? Nat. Rev. Microbiol. 7:367-374.
21. Hotchkiss, R. S., and D. W. Nicholson. 2006. Apoptosis and caspases regulate death and inflammation in sepsis. Nat. Rev. Immunol. 6:813-822.
22. Kerneis, S., A. Bogdanova, J. P. Kraehenbuhl, and E. Pringault. 1997. Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. Science 277:949-952.
23. Kruis, W., P. Fric, J. Pokrotnieks, M. Lukas, B. Fixa, M. Kascak, M. A. Kamm, J. Weismueller, C. Beglinger, M. Stolte, C. Wolff, and J. Schulze. 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617-1623.
24. Ledoux, D., V. J. Labombardi, and D. Karter. 2006. Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease. Int. J. STD AIDS 17:280-282.
25. Lin, H. C., C. H. Hsu, H. L. Chen, M. Y. Chung, J. F. Hsu, R. I. Lien, L. Y. Tsao, C. H. Chen, and B. H. Su. 2008. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 122:693-700.
26. Lupp, C., M. L. Robertson, M. E. Wickham, I. Sekirov, O. L. Champion, E. C. Gaynor, and B. B. Finlay. 2007. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2:204.
27. Macutkiewicz, C., G. Carlson, E. Clark, U. Dobrindt, I. Roberts, and G. Warhurst. 2008. Characterisation of Escherichia coli strains involved in transcytosis across gut epithelial cells exposed to metabolic and inflammatory stress. Microbes Infect. 10:424-431.
28. Martinez-Medina, M., X. Aldeguer, M. Lopez-Siles, F. Gonzalez-Huix, C. Lopez-Oliu, G. Dahbi, J. E. Blanco, J. Blanco, L. J. Garcia-Gil, and A. rfeuille-Michaud. 2009. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm. Bowel Dis. 15:872-882.
29. Mazmanian, S. K., J. L. Round, and D. L. Kasper. 2008. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620-625.
30. Mombaerts, P., J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa, and V. E. Papaioannou. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-877.
31. Neurath, M. F., I. Fuss, M. Pasparakis, L. Alexopoulou, S. Haralambous, K. H. Meyer zum Buschenfelde, W. Strober, and G. Kollias. 1997. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 27:1743-1750.
32. Nikfar, S., R. Rahimi, F. Rahimi, S. Derakhshani, and M. Abdollahi. 2008. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis. Colon Rectum 51:1775-1780.
33. Quigley, E. M. 2006. New perspectives on the role of the intestinal flora in health and disease. J. Gastrointestin. Liver Dis. 15:109-110.
34. Rahimi, R., S. Nikfar, F. Rahimi, B. Elahi, S. Derakhshani, M. Vafaie, and M. Abdollahi. 2008. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig. Dis. Sci. 53:2524-2531.
35. Rembacken, B. J., A. M. Snelling, P. M. Hawkey, D. M. Chalmers, and A. T. Axon. 1999. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354:635-639. (Pubitemid 29391428)
36. Sartor, R. B. 2004. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126:1620-1633.
37. Schlee, M., J. Wehkamp, A. Altenhoefer, T. A. Oelschlaeger, E. F. Stange, and K. Fellermann. 2007. Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect. Immun. 75:2399-2407.
38. Slack, E., S. Hapfelmeier, B. Stecher, Y. Velykoredko, M. Stoel, M. A. Lawson, M. B. Geuking, B. Beutler, T. F. Tedder, W. D. Hardt, P. Bercik, E. F. Verdu, K. D. McCoy, and A. J. Macpherson. 2009. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 325:617-620.
39. Soutourina, O. A., and P. N. Bertin. 2003. Regulation cascade of flagellar expression in Gram-negative bacteria. FEMS Microbiol. Rev. 27:505-523.
40. Stappenbeck, T. S., L. V. Hooper, and J. I. Gordon. 2002. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc. Natl. Acad. Sci. U. S. A. 99:15451-15455.
41. + lymphocytes control gut epithelial apoptosis and mediate survival in sepsis. FASEB J. 23:1817-1825.
42. Sturm, A., K. Rilling, D. C. Baumgart, K. Gargas, T. Abou-Ghazale, B. Raupach, J. Eckert, R. R. Schumann, C. Enders, U. Sonnenborn, B. Wiedenmann, and A. U. Dignass. 2005. Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via Toll-like receptor 2 signaling. Infect. Immun. 73:1452-1465.
43. Thompson, G. R., and P. C. Trexler. 1971. Gastrointestinal structure and function in germ-free or gnotobiotic animals. Gut 12:230-235.
44. Ukena, S. N., A. M. Westendorf, W. Hansen, M. Rohde, R. Geffers, S. Coldewey, S. Suerbaum, J. Buer, and F. Gunzer. 2005. The host response to the probiotic Escherichia coli strain Nissle 1917: specific up-regulation of the proinflammatory chemokine MCP-1. BMC Med. Genet. 6:43.
45. Waidmann, M., O. Bechtold, J. S. Frick, H. A. Lehr, S. Schubert, U. Dobrindt, J. Loeffler, E. Bohn, and I. B. Autenrieth. 2003. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology 125:162-177. (Pubitemid 36799117)
46. Zyrek, A. A., C. Cichon, S. Helms, C. Enders, U. Sonnenborn, and M. A. Schmidt. 2007. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell. Microbiol. 9:804-816.